Teropavimab Biosimilar – Anti-Surface protein gp120 mAb – Research Grade

Description of Teropavimab Biosimilar - Anti-Surface protein gp120 mAb - Research Grade

Introduction

Teropavimab Biosimilar, also known as Anti-Surface protein gp120 mAb, is a research grade monoclonal antibody used for therapeutic purposes. This biosimilar is designed to mimic the structure and activity of the original antibody, which targets the surface protein gp120 of the human immunodeficiency virus (HIV). In this article, we will explore the structure, activity, and potential applications of Teropavimab Biosimilar.

Structure of Teropavimab Biosimilar

Teropavimab Biosimilar is a monoclonal antibody, meaning it is produced by a single clone of immune cells. It is composed of two identical heavy chains and two identical light chains, connected by disulfide bonds. The heavy chains consist of a constant region and a variable region, while the light chains have only a variable region. The variable regions of both chains are responsible for binding to the target protein, gp120.

The structure of Teropavimab Biosimilar is similar to that of the original antibody, with minor modifications to ensure its effectiveness as a biosimilar. These modifications are made to the constant region of the antibody, which does not affect its binding ability but may impact its stability and half-life.

Activity of Teropavimab Biosimilar

Teropavimab Biosimilar functions by binding to the surface protein gp120 of HIV. This protein is essential for the virus to enter and infect host cells. By binding to gp120, Teropavimab Biosimilar prevents the virus from attaching to host cells, thereby inhibiting its ability to infect and replicate.

The binding of Teropavimab Biosimilar to gp120 also triggers an immune response, leading to the destruction of the virus by the body’s immune system. This dual mechanism of action makes Teropavimab Biosimilar a potent therapeutic agent against HIV.

Applications of Teropavimab Biosimilar

Teropavimab Biosimilar has potential applications in both research and clinical settings. In research, this biosimilar can be used to study the structure and function of the original antibody, as well as the mechanism of action of HIV. It can also be used to develop new therapies and treatments for HIV.

In clinical settings, Teropavimab Biosimilar can be used as a therapeutic agent for the treatment of HIV. It can be administered to patients as a single agent or in combination with other antiretroviral drugs. Its ability to target the surface protein of the virus makes it a promising candidate for the treatment of HIV, especially in cases where the virus has developed resistance to other drugs.

Conclusion

Teropavimab Biosimilar, also known as Anti-Surface protein gp120 mAb, is a research grade monoclonal antibody with a similar structure and activity to the original antibody. It binds to the surface protein gp120 of HIV, preventing the virus from infecting host cells and triggering an immune response to destroy the virus. This biosimilar has potential applications in both research and clinical settings, making it a valuable tool in the fight against HIV.

Teropavimab Biosimilar - Anti-Surface protein gp120 mAb binds to HIV1 gp120 / SU recombinant protein in ELISA assay

Immobilized HIV1 gp120 / SU recombinant protein (cat. No. PX-P5202) at 0.5µg/mL (100µL/well) can bind Teropavimab Biosimilar - Anti-Surface protein gp120 mAb (cat. No. PX-TA1793) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 437.5M.